FDA Questions Strength of Evidence Backing Zevra’s Rare Disease Therapy Ahead of Adcomm

The Genetic Metabolic Diseases Advisory Committee will meet on Friday to discuss Zevra’s modified scale to describe the efficacy of its drug candidate for the treatment of Niemann-Pick disease type C.